Methotrexate
In brief
- In our pharmacy, you can buy methotrexate without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging. (Please note methotrexate is normally a prescription medicine and should be used under medical supervision.)
- Methotrexate is used to treat certain cancers, rheumatoid arthritis, psoriatic disease and severe psoriasis; it is an antineoplastic and immunomodulating agent that acts as a folic acid analogue, primarily inhibiting dihydrofolate reductase and interfering with DNA synthesis and cell replication.
- The usual dose depends on the indication: for inflammatory/rheumatic conditions typical low‑dose regimens are 7.5–25 mg once weekly; oncology doses are much higher and vary by protocol (calculated per body surface area or as high‑dose regimens).
- Administration forms include oral tablets (2.5–15 mg), oral solution (2–2.5 mg/ml), injections/vials for intravenous or intramuscular use, and subcutaneous autoinjectors/prefilled syringes.
- Onset: for inflammatory conditions clinical improvement is usually seen within 2–6 weeks (full effect may take up to 3 months); antitumour effects may occur more rapidly depending on regimen.
- Duration of action: plasma half‑life is typically a few hours, but intracellular polyglutamated metabolites persist and allow weekly dosing for autoimmune disease; clinical effects may therefore last for weeks after dosing changes.
- Alcohol warning: avoid or minimise alcohol intake, as alcohol increases the risk of liver toxicity when taking methotrexate.
- The most common side effect is nausea (other frequent effects include mouth ulcers, elevated liver enzymes and blood count changes).
- Would you like to try methotrexate without a prescription?
Basic methotrexate information
- INN (international nonproprietary name): Methotrexate
- Brand names available in the United Kingdom: Jylamvo; Maxtrex; Metoject; Nordimet.
- ATC code: L01BA01.
- Forms and strengths: oral tablets 2.5 mg and 10 mg; oral solution (Jylamvo) 2 mg/ml; injection vials/ampoules 10 mg/ml and 25 mg/ml; prefilled syringes and pens for subcutaneous use.
Legal status and availability in the UK
Methotrexate is a prescription-only medicine (POM) in the UK.
In our online pharmacy, methotrexate is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.
Clinical effectiveness in the UK
Do patients in the NHS actually feel better on methotrexate?
Methotrexate remains the backbone of early rheumatoid arthritis management across NHS trusts.
Clinics use DAS28, HAQ and patient‑reported outcome measures to track benefit, typically seeing meaningful improvement within 8–12 weeks when adherence and monitoring are maintained.
Some patients gain better symptom control after switching from oral tablets to subcutaneous devices such as Metoject.
- DAS28 — disease activity score used widely in RA clinics.
- HAQ — health assessment questionnaire for functional status.
- Patient‑reported outcomes — fatigue, pain scores and quality of life measures.
| Attribute | Oral methotrexate | Subcutaneous methotrexate |
|---|---|---|
| Bioavailability | Good at low doses; variable at higher doses | Higher and more consistent |
| Tolerability (GI) | More GI side‑effects in some patients | Reduced GI intolerance; devices like Metoject help |
| Patient Preference | Prefer tablets for convenience | Preferred when oral absorption or side‑effects limit benefit |
Indications and expanded uses
What is methotrexate licensed for, and when is it used off‑label?
Methotrexate is classified under ATC L01BA01 as an antineoplastic and immunomodulating agent.
Low‑dose weekly methotrexate is standard and licensed for rheumatoid arthritis and severe psoriasis in routine NHS practice.
High‑dose regimens are used in oncology protocols for solid tumours and haematological malignancies with specialist monitoring and leucovorin rescue.
In NHS practice, clinicians also use methotrexate in some off‑label settings when guideline evidence supports that use, for example single‑dose intramuscular regimens for medical management of ectopic pregnancy under RCOG guidance.
Specialist dermatology and ophthalmology clinics may prescribe methotrexate off‑label for inflammatory conditions when benefit outweighs risk and monitoring is in place.
- Licensed uses: Rheumatoid arthritis; severe psoriasis; oncology protocols (high dose).
- Off‑label uses (NHS/selected clinics): Medical management of ectopic pregnancy (single‑dose IM), certain inflammatory dermatology and ophthalmology indications.
| Indication | Typical weekly dose | Route |
|---|---|---|
| Low‑dose Immunomodulation (RA, Psoriasis) | 7.5–25 mg weekly | Oral or subcutaneous |
| Oncology (Selected Protocols) | High doses per protocol | Intravenous or intrathecal in specialist settings |
Composition and brand landscape
Which brands and formulations are available for prescribing or dispensing in the UK?
The active ingredient is methotrexate, an antimetabolite and folic acid analogue classified under ATC L01BA01.
Available UK brands and clinically relevant forms include Jylamvo oral solution, Metoject prefilled syringes or auto‑injectors, Nordimet prefilled syringes and generic tablets.
Typical packaging for oral tablets is blister strips or bottles, while oral liquids come in bottles and injections as vials or prefilled devices.
| Brand | Form | Typical packaging | Likely NHS availability |
|---|---|---|---|
| Jylamvo | Oral solution (2 mg/ml) | Bottle | Available |
| Metoject / Metex | Prefilled syringe / auto‑injector | Prefilled devices | Available; used for SC administration |
| Nordimet | Prefilled syringe | Prefilled devices | Available |
| Generic Methotrexate | Tablets 2.5 mg and 10 mg; injection 10/25 mg/ml | Blisters, vials | Widely available |
Generic methotrexate tablets in the UK come as 2.5 mg and 10 mg; oral liquid and injection formulations are options for patients with swallowing difficulties or intolerance to tablets.
Contraindications and special precautions
Who must not take methotrexate, and what precautions should be taken?
Absolute contraindications include pregnancy and lactation due to teratogenicity and severe hepatic impairment.
Other contraindications and high‑risk groups include significant immunodeficiency and active uncontrolled infection.
Severe renal impairment requires dose adjustment or avoidance because of reduced clearance and higher toxicity risk.
Elderly, frail patients and heavy alcohol consumers are higher risk and need careful assessment and monitoring.
Standard NHS precautions include baseline and ongoing monitoring of liver function tests, full blood count and renal function to detect hepatotoxicity and cytopenias early.
- Absolute contraindications: Pregnancy; breastfeeding; severe hepatic impairment; known severe immunodeficiency.
- High‑risk groups: Severe renal impairment; elderly frail patients; active infections; heavy alcohol users.
| Monitoring trigger | Action |
|---|---|
| Raised ALT/AST (>3× ULN) | Pause methotrexate; investigate liver causes |
| Significant Cytopenia (neutropenia, thrombocytopenia) | Stop methotrexate; consider haematology review |
| New Persistent Cough or Dyspnoea | Assess for pneumonitis; consider chest X‑ray and specialist review |
Patients are commonly counselled in UK practice to avoid or minimise alcohol, to postpone live vaccines while immunosuppressed and to discuss contraception thoroughly before starting methotrexate.
Dosage guidelines
How should weekly methotrexate be dosed and adjusted in routine NHS practice?
NHS regimens for inflammatory indications use once‑weekly dosing with typical starting ranges of 7.5–15 mg once weekly, titrated to 20–25 mg weekly as tolerated.
Some clinicians start at 10–15 mg weekly depending on disease severity and patient factors.
Folic acid supplementation is routine to reduce mucosal and hepatic side effects, commonly given as 5–10 mg weekly or 1 mg daily except on the methotrexate day.
When oral tolerance or absorption is poor, subcutaneous or intramuscular administration via devices such as Metoject or Nordimet provides higher bioavailability and often improved efficacy.
Oncology dosing is protocol‑driven and involves much higher doses with specialised monitoring and leucovorin rescue; those regimens are managed in secondary care.
| Indication | Typical weekly dose | Route | Folic acid advice |
|---|---|---|---|
| Rheumatoid Arthritis, Psoriasis | 7.5–25 mg once weekly | Oral or subcutaneous | 5–10 mg weekly or 1 mg daily (except MTX day) |
| Poor Oral Tolerance/Absorption | Equivalent weekly dose | Subcutaneous (Metoject, Nordimet) | Same folic acid approach |
| Oncology Protocols | High dose per protocol | IV/IM/IT in specialist setting | Leucovorin rescue as specified |
- Weekly dosing rules: Choose a single weekday and stick to it; never take daily dosing unless specifically instructed for oncology.
- Missed doses: do not double up; contact clinic for advice.
Interactions overview
Which medicines and substances increase methotrexate risk?
Several interactions can potentiate marrow suppression or reduce methotrexate clearance.
Trimethoprim/sulfamethoxazole is known to increase the risk of bone‑marrow suppression when combined with methotrexate.
Certain NSAIDs and aminoglycoside antibiotics can affect renal excretion and thus increase methotrexate levels in some cases.
Proton pump inhibitors have been associated in reports with altered methotrexate clearance, so caution and individual review are advised.
Live vaccines are contraindicated during significant immunosuppression, and alcohol potentiates hepatotoxicity.
- High‑risk drug interactions: Trimethoprim/sulfamethoxazole; some NSAIDs; certain antibiotics affecting renal function.
- Food/drink: Alcohol increases liver risk; avoid herbal hepatotoxins without review.
| Interaction mechanism | Clinical advice |
|---|---|
| Reduced Renal Clearance (NSAIDs/aminoglycosides) | Review concurrent use; monitor renal function and methotrexate toxicity signs |
| Bone‑Marrow Potentiation (Trimethoprim) | Avoid combination where possible; monitor FBC closely |
| Altered Clearance (PPI Reports) | Assess benefit/risk; consider alternative acid suppression if required |
Pharmacists commonly advise patients to bring an up‑to‑date medicines list to every consultation to check for interactions with methotrexate.
Comparable medicines and preferences
What are the common alternatives when methotrexate is unsuitable?
NHS pathways commonly consider sulfasalazine, hydroxychloroquine and leflunomide as alternatives or combination partners for conventional DMARD therapy.
When escalation is needed, biologics such as TNF inhibitors and IL‑6 inhibitors are considered, often in combination with methotrexate or as replacements.
Key choice factors include efficacy, toxicity profile, monitoring burden and pregnancy planning.
- Hydroxychloroquine — lower pregnancy risk compared with methotrexate; less monitoring burden.
- Leflunomide — efficacious but has hepatotoxicity concerns and long washout considerations.
- Sulfasalazine — option for combination therapy with different side‑effect profile.
| Attribute | Methotrexate | Hydroxychloroquine | Leflunomide |
|---|---|---|---|
| Efficacy (RA) | High; first line | Moderate | High |
| Monitoring | Frequent LFT/FBC/renal | Less frequent monitoring | Regular LFTs; long washout if needed |
| Pregnancy Compatibility | Contraindicated | Generally tolerated | Contraindicated / washout needed |
Frequently asked questions
Q: Can I drink alcohol while taking methotrexate?
A: Minimise alcohol; many UK clinicians advise abstaining or keeping consumption very low to reduce hepatic risk and to ensure regular LFT monitoring.
Q: What if I miss a weekly dose?
A: Do not double up; if you realise within 24 hours contact your clinic or pharmacist for advice; otherwise skip and take the next scheduled weekly dose after confirming with your care team.
Q: How often will I need blood tests?
A: Typical NHS monitoring is baseline tests, then bloods at 2–4 weeks after initiation, and every 2–3 months once stable; monitoring increases with dose changes or complications.
Q: Can I become pregnant or father a child while on methotrexate?
A: Methotrexate is teratogenic; women must stop methotrexate and follow specialist contraception guidance and men should discuss fertility planning with their clinic for tailored advice and timing.
Guidelines for proper use
What should pharmacists tell patients starting methotrexate?
Confirm the chosen weekly dosing day and ensure the patient understands never to take daily dosing for immunomodulation regimens.
Reinforce the folic acid regimen and explain timing relative to the methotrexate dose.
Review other medicines including OTC and herbal products and advise on interactions with trimethoprim, certain NSAIDs and proton pump inhibitors where relevant.
Highlight red‑flag symptoms requiring urgent review such as fever, sore throat, unexplained bruising or bleeding, jaundice and new persistent breathlessness.
Arrange monitoring reminders and signpost NHS portals for blood result access.
- Counselling checklist: Confirm weekly dose day; advise folic acid; review medicines; discuss contraception; explain red flags; arrange monitoring reminders.
| Monitoring point | Timing |
|---|---|
| Baseline (FBC, LFTs, Renal) | Before starting |
| Early Check | 2–4 weeks after initiation |
| Maintenance | Every 2–3 months when stable |
Pharmacists are encouraged to help patients report adverse reactions via the MHRA Yellow Card scheme and to provide written safety leaflets and NHS App signposting.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Liverpool | England | 9–21 days |
| Bristol | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
Final notes
If you are starting methotrexate, ask your clinic about switching to a subcutaneous device such as Metoject if you have GI side‑effects or poor tablet absorption.
Keep an up‑to‑date medicines list and use the NHS App to view blood results and clinic messages where available.
For pregnancy or fertility questions, seek specialist referral from your rheumatology, dermatology or obstetrics team promptly.
Report suspected adverse reactions via the MHRA Yellow Card scheme and ask your pharmacist for help with reporting if needed.
